疏肝解郁胶囊联合艾司西酞普兰治疗卒中后抑郁患者的临床效果

Clinical Effect of Shugan Jieyu Capsules Combined with Escitalopram in Patients with Post-stroke Depression

目的:探讨疏肝解郁胶囊联合艾司西酞普兰治疗卒中后抑郁患者的临床效果。方法:选取2020年6月—2022年4月在湖北科技学院附属第一医院收治的卒中后抑郁患者100例,按照随机数表法将其分为研究组(n=50)和对照组(n=50)。对照组给予艾司西酞普兰治疗,研究组给予疏肝解郁胶囊联合艾司西酞普兰治疗。比较两组临床疗效、抑郁症状、神经功能及同型半胱氨酸(Hcy)、C反应蛋白(CRP)水平。结果:研究组治疗总有效率为98.00%,高于对照组的84.00%,差异有统计学意义(P<0.05);治疗后,两组汉密尔顿抑郁状态量表(HAMD)评分较治疗前降低,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组美国国立卫生院卒中量表(NIHSS)评分较治疗前降低,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组Hcy、CRP水平较治疗前降低,且研究组低于对照组,差异有统计学意义(P<0.05)。结论:卒中后抑郁患者采用疏肝解郁胶囊与艾司西酞普兰联合治疗,能够提高临床效果,改善抑郁症状及神经功能,降低Hcy、CRP水平。

Objective:To explore the clinical effect of Shugan Jieyu Capsules combined with Escitalopram in the treatment of post-stroke depression.Method:A total of 100 patients with post-stroke depression who were treated in the First Affiliated Hospital of Hubei University of Science and Technology from June 2020 to April 2022 were selected,and they were divided into study group(50 cases)and control group(50 cases)by the random number table Method.The control group was treated with Escitalopram,and the study group was treated with Shugan Jieyu Capsules combined with Escitalopram.The clinical efficacy,depressive symptoms,neural function,homocysteine(Hcy)and C-reactive protein(CRP)levels of the two groups were compared.Result:The total effective rate in the study group was 98.00%,which was higher than 84.00%in the control group,the difference was statistically significant(P<0.05).After treatment,the scores of Hamilton depression scale(HAMD)in both groups were decreased than those before treatment,and the scores in the study group were lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the scores of National Institute of Health stroke scale(NIHSS)in both groups were decreased than those before treatment,and the scores in the study group was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the Hcy and CRP levels in both groups decreased than those before treatment,and the levels in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:The combination of Shugan Jieyu Capsules and Escitalopram can improve the clinical efficacy,improve the depressive symptoms and neurological function,and reduce the level of Hcy and CRP in patients with post-stroke depression.